ADOA PROGRAM – PRESENTATION AT NANOS 2026
March 24, 2026 – Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical – NANOS 2026, PYC Therapeutics, autosomal dominant optic atrophy, clinical trials, ophthalmology, precision medicine
- PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available
- One of PYC’s clinical-stage programs is an investigational drug candidate (known as PYC-001) that targets the underlying cause of a blinding eye disease of childhood called Autosomal Dominant Optic Atrophy (ADOA)
- PYC today announces that safety and efficacy data from a Single Ascending Dose study of PYC-001 in ADOA patients1 will be presented by Dr. Clare Fraser at the North American Neuro-Ophthalmology Society (NANOS) 2026 Conference in Boston, MA between 20-24 March 2026 – a copy of Dr. Fraser’s presentation is attached to this announcement
- PYC has recently commenced a Multiple-Ascending Dose (MAD) study of PYC-001 in ADOA patients2 with clinical safety and efficacy data from this repeat dose study expected to be presented in H2 CY263.
24 March 2026 — Perth, Australia and California, US — PYC Therapeutics Limited is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.
The Company currently has three clinical-stage drug development programs including a drug candidate (known as PYC-001) that addresses the underlying cause of Autosomal Dominant Optic Atrophy (ADOA). ADOA affects 1 in every 35,0004 people and there are currently no approved treatment options available for patients.
PYC today announces that clinical data from the Single Ascending Dose (SAD) study of PYC001 in ADOA patients will be presented by Dr. Clare Fraser at the North American NeuroOphthalmology Society (NANOS) 2026 conference in Boston, Massachusetts. The presentation will highlight the safety/tolerability and efficacy results of single doses of PYC-001 demonstrated in the study.
PYC recently commenced a repeat dose study of PYC-001 in ADOA patients and expects to present clinical safety and efficacy data from this study in H2 CY265.
About PYC Therapeutics
PYC Therapeutics is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC’s drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development. For more information, visit pyctx.com.
